Sanara MedTech Inc. (SMTI) Stock

Sanara MedTech Inc. (SMTI) is a Healthcare stock trading at $34.26 (as of 2026-08-20), with a market capitalization of $313.96M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Sanara MedTech Inc. develops, markets, and distributes wound and skin care products in the United States, including surgical and wound dressings and related extracellular-matrix and collagen-based therapies. Its products are used by physicians and provided through hospitals, clinics, and post-acute care settings.

Understand Sanara MedTech Inc.: how it makes money

Sanara MedTech develops, markets, and distributes wound and skin care products for use in U.S. hospitals, clinics, and post-acute care settings, making money by selling its surgical activated collagen and antimicrobial wound care products through physician, facility, and selling-channel access.

The profit model appears to be driven by turning selling-channel access (approved and contracted hospitals and ambulatory surgery centers, plus states) into actual product sales, because the company’s reported gross margin is high while the provided revenue scale for the latest period is very small.

Revenue by segment (latest quarter)
Scenera$0.0B

Business quality (Mixed): Clear, facility-level KPIs to track commercial traction, but the latest period shows effectively zero revenue in the provided financials, which can make operating results harder to interpret.

Bull case

  • Very high gross margin is reported for the latest period (93.1%): If sales volume grows while gross margin holds, profitability could improve.
  • Commercial footprint metrics are tracked with specific facility and approval counts, including Hospitals and Ambulatory Surgery Centers Sold (1200) and Approved Facilities for Cellrate Rx (1250): This suggests a measurable path from approvals and contracts to where products are actually sold.

Bear case

  • The latest period’s reported revenue is 0.0B in the provided financials (2026-03-31): Low or timing-impacted revenue can make quarter-to-quarter operating performance volatile and harder to forecast.
  • Segment operating and profitability metrics shown in the dataset include Surgical Segment Net Loss (0.0) and Tissue Health Plus Segment Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (0.0): This raises uncertainty about whether the business model is consistently generating meaningful operating profit in the near term.
Valuation — source: SEC EDGAR (first-party)
Price$34.26
Market Cap$313.96M
EV / EBITDA27.8
Price / Book39.57
Price / Sales2.85
FCF Yield-2.3%
DCF Value (model)$7.13
DCF Upside vs Price-79.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$103.12M
Net Margin-36.4%
Revenue Growth (YoY)19.0%
EPS Growth (YoY)282.5%
FCF Growth (YoY)-1041.1%
Financial Health — source: SEC EDGAR
Altman Z-Score3.36 (safe)
Piotroski F-Score4/9 (moderate)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($4.28M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOSeth D. Yon
Employees141
CountryUS
IPO Date1994-04-07

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Enovis Corporation (ENOV)
  • Cadre Holdings, Inc. (CDRE)
  • Avanos Medical, Inc. (AVNS)
  • Conexeu Sciences Inc. (CNXU)
  • Inogen, Inc. (INGN)
  • Lakeland Industries, Inc. (LAKE)
  • Safe Pro Group Inc. Common Stock (SPAI)
  • Myomo, Inc. (MYO)
SMTI earnings history · SMTI institutional & insider holders · SMTI KPIs & operating metrics · SMTI financials · SMTI investor presentations & press releases · SMTI SEC filings · SMTI peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.